<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>The Neuroscience Journal of Shefaye Khatam</title>
<title_fa>مجله علوم اعصاب شفای خاتم</title_fa>
<short_title>Shefaye Khatam</short_title>
<subject>Medical Sciences</subject>
<web_url>http://shefayekhatam.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-1887</journal_id_issn>
<journal_id_issn_online>2345-4814</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/shefa</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>fa</language>
<pubdate>
	<type>jalali</type>
	<year>1403</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2024</year>
	<month>11</month>
	<day>1</day>
</pubdate>
<volume>12</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>fa</language>
	<article_id_doi></article_id_doi>
	<title_fa>Berberine Attenuates Convulsing Behavior in 4-aminopyridine Treated Rats</title_fa>
	<title>Berberine Attenuates Convulsing Behavior in 4-aminopyridine Treated Rats</title>
	<subject_fa>نورولوژی</subject_fa>
	<subject>Neurology</subject>
	<content_type_fa>خلاصه مقاله همایش</content_type_fa>
	<content_type>Conference Paper Abstract</content_type>
	<abstract_fa>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; 4-Aminopyridine (4-AP), a K+ channel blocker, causes seizures by stimulating the release of glutamate from nerve terminals. The natural isoquinoline alkaloid berberine has neuroprotective properties. The present study aimed to investigate the effect of berberine on seizure onset produced by 4-AP in rats. &lt;strong&gt;Materials and Methods:&lt;/strong&gt; The rats were given berberine (50, 100, and 200 mg/kg, IP) 40 min before administration of 4-AP (15 mg/kg, IP), and the onset of seizure was recorded. Additionally, diazepam (DZP, 15 mg/kg, IP) was given to a group of rats 20 minutes before 4-AP was administered. &lt;strong&gt;Results: &lt;/strong&gt;The beginning of the seizure was markedly postponed by berberine following the 4-AP injection. &lt;strong&gt;Conclusion: &lt;/strong&gt;Our findings imply that berberine may be able to stop seizures brought on by 4-AP. This research highlights the therapeutic potential of berberine to treat neurological diseases.&lt;br&gt;
&amp;nbsp;&lt;/div&gt;</abstract_fa>
	<abstract>&lt;strong&gt;Introduction:&lt;/strong&gt; 4-Aminopyridine (4-AP), a K+ channel blocker, causes seizures by stimulating the release of glutamate from nerve terminals. The natural isoquinoline alkaloid berberine has neuroprotective properties. The present study aimed to investigate the effect of berberine on seizure onset produced by 4-AP in rats. &lt;strong&gt;Materials and Methods:&lt;/strong&gt; The rats were given berberine (50, 100, and 200 mg/kg, IP) 40 min before administration of 4-AP (15 mg/kg, IP), and the onset of seizure was recorded. Additionally, diazepam (DZP, 15 mg/kg, IP) was given to a group of rats 20 minutes before 4-AP was administered. &lt;strong&gt;Results: &lt;/strong&gt;The beginning of the seizure was markedly postponed by berberine following the 4-AP injection. &lt;strong&gt;Conclusion: &lt;/strong&gt;Our findings imply that berberine may be able to stop seizures brought on by 4-AP. This research highlights the therapeutic potential of berberine to treat neurological diseases.&lt;br&gt;
&amp;nbsp;</abstract>
	<keyword_fa>Seizures, Plants, Medicinal, Epilepsy</keyword_fa>
	<keyword>Seizures, Plants, Medicinal, Epilepsy</keyword>
	<start_page>4</start_page>
	<end_page>4</end_page>
	<web_url>http://shefayekhatam.ir/browse.php?a_code=A-11-24-1440&amp;slc_lang=fa&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Fatemeh</first_name>
	<middle_name></middle_name>
	<last_name>Forouzanfar</last_name>
	<suffix></suffix>
	<first_name_fa>Fatemeh</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Forouzanfar</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>forouzanfarf@mums.ac.ir</email>
	<code>100319475328460027325</code>
	<orcid>100319475328460027325</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
	<affiliation_fa>Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation_fa>
	 </author>


	<author>
	<first_name>Hamid Reza</first_name>
	<middle_name></middle_name>
	<last_name>Sadeghnia</last_name>
	<suffix></suffix>
	<first_name_fa>Hamid Reza</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Sadeghnia</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460027326</code>
	<orcid>100319475328460027326</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa>Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Ali Reza</first_name>
	<middle_name></middle_name>
	<last_name>Taji</last_name>
	<suffix></suffix>
	<first_name_fa>Taji</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Ali Reza</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460027327</code>
	<orcid>100319475328460027327</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa>Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Hossein</first_name>
	<middle_name></middle_name>
	<last_name>Hosseinzadeh</last_name>
	<suffix></suffix>
	<first_name_fa>Hossein</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Hosseinzadeh</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460027328</code>
	<orcid>100319475328460027328</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa>Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
